Citations

Clear

6274 citation(s) found for "To, Andrew".

Effects of a Multi-Ingredient Preworkout Supplement Versus Caffeine on Energy Expenditure and Feelings of Fatigue during Low-Intensity Treadmill Exercise in College-Aged Males
Lutsch, Daniel J., Camic, Clayton L., Jagim, Andrew R. , Stefan, Riley R., Cox, Brandon J., Tauber, Rachel, Henert, Shaine , Jagim, Andrew R , Tauber, Rachel N.

Mayo Clinic

Sports | September 25, 2020 | Volume: 8 | Issue: 10 | Pages: 132

10.3390/sports8100132 | PMID 32992830 Get It

The primary purpose of this study was to examine the acute effects of a multi-ingredient (i.e., caffeine, green tea extract, Yohimbe extract, capsicum annum, coleus extract, L-carnitine, beta-alanine, tyrosine) preworkout supplement versus a dose of caffeine (6 mg·kg−1) on energy expenditure during low-intensity exercise. The effects of these treatments on substrate utilization, gas exchange, and psychological factors were also investigated. Twelve males (mean ± SD: age = 22.8 ± 2.4 years) completed three bouts of 60 min of treadmill exercise on separate days after consuming a preworkout supplement, 6 mg·kg−1 of caffeine, or placebo in a randomized fashion. The preworkout and caffeine supplements resulted in significantly greater energy expenditure (p < 0.001, p = 0.006, respectively), V˙O2 (p < 0.001, p = 0.007, respectively), V˙CO2 (p = 0.006, p = 0.049, respectively), and V˙E (p < 0.001, p = 0.007, respectively) compared to placebo (collapsed across condition). There were no differences among conditions, however, for rates of fat or carbohydrate oxidation or respiratory exchange ratio. In addition, the preworkout supplement increased feelings of alertness (p = 0.015) and focus (p = 0.005) 30-min postingestion and decreased feelings of fatigue (p = 0.014) during exercise compared to placebo. Thus, the preworkout supplement increased energy expenditure and measures of gas exchange to the same extent as 6 mg·kg−1 of caffeine with concomitant increased feelings of alertness and focus and decreased feelings of fatigue.
Prevalence of and Recovery From Anemia Following Hospitalization for Critical Illness Among Adults
Hanson, Andrew C. , Frank, Ryan D. , Schulte, Phillip J. , Storlie, Curtis B. , Kor, Daryl J. , Warner, Matthew A. , Go, Ronald S.

Mayo Clinic

JAMA Network Open | September 24, 2020 | Volume: 3 | Issue: 9 | Pages: e2017843

10.1001/jamanetworkopen.2020.17843 | PMID 32970158 Get It

Opsoclonus in Anti-Ma2 Brain-Stem Encephalitis
Kunchok, Amy , Pittock, Sean J , McKeon, Andrew

Mayo Clinic

New England Journal of Medicine | September 23, 2020 | Volume: 383 | Issue: 13 | Pages: No page available

10.1056/nejmicm1914516 | PMID 32966725 Get It

Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma
Munshi, Pashna N. , Vesole, David H. , Martin, Andrew St., Dávila, Omar, Badawy, Sherif M. , Copelan, Edward A. , Kharfan‐Dabaja, Mohamed A. , Farhadfar, Nosha , Ganguly, Siddhartha , Hashmi, Shahrukh K. , Krem, Maxwell M. , Malek, Ehsan , Meehan, Kenneth R., Murthy, Hemant S. , Olin, Rebecca L. , Schriber, Jeffrey, Seo, Sachiko , Shah, Gunjan L. , Solh, Melhem , Tay, Jason , Kumar, Shaji , Qazilbash, Muzaffar H. , Shah, Nina , D’Souza, Anita , Farhadfar, Nosha , Hashmi, Shahrukh K , Malek, Ehsan , Kumar, Shaji K , Qazilbash, Muzaffar H , Shah, Nina , D'Souza, Anita , Murthy, Hemant S , Badawy, Sherif M , Shah, Gunjan L , Jurczyszyn, Artur , Zaucha, Jan Maciej , Agrawal, Vaibhav , Battiwalla, Minoo , Chhabra, Saurabh , Lazarus, Hillard M. , Nishihori, Taiga , Olsson, Richard F. , Hari, Parameswaran

Mayo Clinic

Cancer | September 23, 2020 | Volume: 126 | Issue: 23 | Pages: 5077-5087

10.1002/cncr.33171 | PMID 32965680 Get It

BackgroundUpfront autologous hematopoietic stem cell transplantation (AHCT) remains an important therapy in the management of patients with multiple myeloma (MM), a disease of older adults.MethodsThe authors investigated the outcomes of AHCT in patients with MM who were aged ≥70 years. The Center for International Blood and Marrow Transplant Research (CIBMTR) database registered 15,999 patients with MM in the United States within 12 months of diagnosis during 2013 through 2017; a total of 2092 patients were aged ≥70 years. Nonrecurrence mortality (NRM), disease recurrence and/or progression (relapse; REL), progression‐free survival (PFS), and overall survival (OS) were modeled using Cox proportional hazards models with age at transplantation as the main effect. Because of the large sample size, a P value <.01 was considered to be statistically significant a priori.ResultsAn increase in AHCT was noted in 2017 (28%) compared with 2013 (15%) among patients aged ≥70 years. Although approximately 82% of patients received melphalan (Mel) at a dose of 200 mg/m2 overall, 58% of the patients aged ≥70 years received Mel at a dose of 140 mg/m2. On multivariate analysis, patients aged ≥70 years demonstrated no difference with regard to NRM (hazard ratio [HR] 1.3; 99% confidence interval [99% CI], 1‐1.7 [P = .06]), REL (HR, 1.03; 99% CI, 0.9‐1.1 [P = 0.6]), PFS (HR, 1.06; 99% CI, 1‐1.2 [P = 0.2]), and OS (HR, 1.2; 99% CI, 1‐1.4 [P = .02]) compared with the reference group (those aged 60‐69 years). In patients aged ≥70 years, Mel administered at a dose of 140 mg/m2 was found to be associated with worse outcomes compared with Mel administered at a dose of 200 mg/m2, including day 100 NRM (1% [95% CI, 1%‐2%] vs 0% [95% CI, 0%‐1%]; P = .003]), 2‐year PFS (64% [95% CI, 60%‐67%] vs 69% [95% CI, 66%‐73%]; P = .003), and 2‐year OS (85% [95% CI, 82%‐87%] vs 89% [95% CI, 86%‐91%]; P = .01]), likely representing frailty.ConclusionsThe results of the current study demonstrated that AHCT remains an effective consolidation therapy among patients with MM across all age groups.
Occipital-Cervical Fusion and Ventral Decompression in the Surgical Management of Chiari-1 Malformation and Syringomyelia: Analysis of Data From the Park-Reeves Syringomyelia Research Consortium
CreveCoeur, Travis S. , Yahanda, Alexander T. , Maher, Cormac O. , Johnson, Gabrielle W. , Ackerman, Laurie L. , Adelson, P. David , Albert, Gregory W. , Aldana, Phillipp R, Alden, Tord D. , Anderson, Richard C. E. , Baird, Lissa , Bauer, David F. , Bierbrauer, Karin S. , Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel E., Daniels, David, Dauser, Robert C., Durham, Susan, Ellenbogen, Richard G. , Eskandari, Ramin , Fuchs, Herbert E., George, Timothy M., Greene, Stephanie , Gross, Naina L. , Guillaume, Daniel, Hankinson, Todd C. , Heuer, Gregory G. , Iantosca, Mark, Iskandar, Bermans J. , Jackson, Eric M. , Jea, Andrew, Johnston, James M. , Keating, Robert F., Kelly, Michael P. , Khan, Nickalus R. , Krieger, Mark D., Leonard, Jeffrey R. , Mangano, Francesco T. , Mapstone, Timothy B., McComb, J. Gordon , Muhlbauer, Michael S., Oakes, W. Jerry, Olavarria, Greg, O’Neill, Brent R., Park, Tae Sung, Ragheb, John , Shannon, Chevis N. , Smith, Jodi L. , Stone, Scellig , Strahle, Jennifer M. , Tamber, Mandeep S. , Torner, James C., Tuite, Gerald F. , Wait, Scott D. , Wellons, John C. , Whitehead, William E. , Limbrick, David D. , Torner, James C. , Kelly, Michael P , Yahanda, Alexander T , Ahmed, Raheel , Aldana, Phillip R., Grant, Gerald A. , Graupman, Patrick C. , Greenfield, Jeffrey P. , Guillaume, Daniel J, Haller, Gabe , Menezes, Arnold H. , Selden, Nathan R. W. , Shah, Manish N. , Shimony, Joshua S. , Limbrick, David D.

Mayo Clinic

Neurosurgery | September 22, 2020 | Volume: 88 | Issue: 2 | Pages: 332-341

10.1093/neuros/nyaa460 | PMID 33313928 Get It

Abstract BACKGROUND Occipital-cervical fusion (OCF) and ventral decompression (VD) may be used in the treatment of pediatric Chiari-1 malformation (CM-1) with syringomyelia (SM) as adjuncts to posterior fossa decompression (PFD) for complex craniovertebral junction pathology. OBJECTIVE To examine factors influencing the use of OCF and OCF/VD in a multicenter cohort of pediatric CM-1 and SM subjects treated with PFD. METHODS The Park-Reeves Syringomyelia Research Consortium registry was used to examine 637 subjects with cerebellar tonsillar ectopia ≥ 5 mm, syrinx diameter ≥ 3 mm, and at least 1 yr of follow-up after their index PFD. Comparisons were made between subjects who received PFD alone and those with PFD + OCF or PFD + OCF/VD. RESULTS All 637 patients underwent PFD, 505 (79.2%) with and 132 (20.8%) without duraplasty. A total of 12 subjects went on to have OCF at some point in their management (PFD + OCF), whereas 4 had OCF and VD (PFD + OCF/VD). Of those with complete data, a history of platybasia (3/10, P = .011), Klippel-Feil (2/10, P = .015), and basilar invagination (3/12, P < .001) were increased within the OCF group, whereas only basilar invagination (1/4, P < .001) was increased in the OCF/VD group. Clivo-axial angle (CXA) was significantly lower for both OCF (128.8 ± 15.3°, P = .008) and OCF/VD (115.0 ± 11.6°, P = .025) groups when compared to PFD-only group (145.3 ± 12.7°). pB-C2 did not differ among groups. CONCLUSION Although PFD alone is adequate for treating the vast majority of CM-1/SM patients, OCF or OCF/VD may be occasionally utilized. Cranial base and spine pathologies and CXA may provide insight into the need for OCF and/or OCF/VD.
Autism BrainNet: A Collaboration Between Medical Examiners, Pathologists, Researchers, and Families to Advance the Understanding and Treatment of Autism Spectrum Disorder
Quinton, Reade A. , Kelly, Karen, Falzon, Andrew, Halladay, Alycia , Schumann, Cynthia M. , Tamminga, Carol A. , Hare, Carolyn Komich, Quinton, Reade, Anderson, Matthew P. , Falzon, Andrew L., Hof, Patrick R. , Amaral, David Gil

Mayo Clinic

Archives of Pathology & Laboratory Medicine | September 22, 2020 | Volume: 145 | Issue: 4 | Pages: 494-501

10.5858/arpa.2020-0164-ra | PMID 32960953 Get It

Context.— Autism spectrum disorder is a neurodevelopmental condition that affects over 1% of the population worldwide. Developing effective preventions and treatments for autism will depend on understanding the neuropathology of the disorder. While evidence from magnetic resonance imaging indicates altered development of the autistic brain, it lacks the resolution needed to identify the cellular and molecular underpinnings of the disorder. Postmortem studies of human brain tissue currently represent the only viable option to pursuing these critical studies. Historically, the availability of autism brain tissue has been extremely limited. Objective.— To overcome this limitation, Autism BrainNet, funded by the Simons Foundation, was formed as a network of brain collection sites that work in a coordinated fashion to develop a library of human postmortem brain tissues for distribution to researchers worldwide. Autism BrainNet has collection sites (or Nodes) in California, Texas, and Massachusetts; affiliated, international Nodes are located in Oxford, England and Montreal, Quebec, Canada. Data Sources.— Pubmed, Autism BrainNet. Conclusions.— Because the death of autistic individuals is often because of an accident, drowning, suicide, or sudden unexpected death in epilepsy, they often are seen in a medical examiner's or coroner's office. Yet, autism is rarely considered when evaluating the cause of death. Advances in our understanding of chronic traumatic encephalopathy have occurred because medical examiners and neuropathologists questioned whether a pathologic change might exist in individuals who played contact sports and later developed severe behavioral problems. This article highlights the potential for equally significant breakthroughs in autism arising from the proactive efforts of medical examiners, pathologists, and coroners in partnership with Autism BrainNet.
Trends in reported industry payments to physicians practicing cardiac electrophysiology from 2013 to 2018 in the United States
Tseng, Andrew S. , Hu, Tiffany , Lee, Justin Z. , Amin, Mustapha, Vaidya, Vaibhav R. , Deshmukh, Abhishek , Madhavan, Malini , Cha, Yong‐Mei , Asirvatham, Samuel J. , Mulpuru, Siva K. , Hu, Tiffany Y, Vaidya, Vaibhav , Tseng, A S , Asirvatham, Samuel J

Mayo Clinic

Journal of Cardiovascular Electrophysiology | September 21, 2020 | Volume: 31 | Issue: 12 | Pages: 3106-3114

10.1111/jce.14754 | PMID 32955151 Get It

AbstractIntroductionThe need for transparency in financial relationships in the healthcare system, has culminated in Open Payments database, managed by the Center for Medicare and Medicaid Services (CMS). Since its inception in 2013, the trend in such payments to physicians practicing cardiac electrophysiology was not examined.Methods and ResultsPayment information reported to CMS from January 2013 to December 2018 was obtained from the publicly available Open Payments data set using the online query tool. The data were analyzed by an individual provider and by state. An in‐depth analysis of payments in the year 2018 payments was performed. From 2014 to 2018, there was an 18% increase in the total number of payments reported from 88 877 payments in 2014 to 105 000 in 2018. Despite the increase in the total number of payments reported, the average payment steadily decreased over time, resulting in an overall reduction in the total amount of payments from 2014 to 2018 ($34.9 million to $28.2 million). Payments to the top 5% of individual recipients have also decreased over this time. In 2018, 2888 unique providers received reportable payments, a total of 105 000 payments, with a median payment amount of $1378 (interquartile range: $165–$5781). The majority of these payments were for food and beverage (82%) and travel/lodging (10%). The top five payers include Boston Scientific, Medtronic Vascular, Abbott Laboratories, Janssen Pharmaceuticals, and Biotronik.ConclusionAmong cardiac electrophysiologists, there is increased reporting of payments in the Open Payments program over time, with a notable decrease in the payment amount.
A Preclinical Animal Study of Combined Intragastric Balloon and Duodenal-Jejunal Bypass Liner for Obesity and Metabolic Disease
Ghoz, Hassan , Jaruvongvanich, Veeravich , Matar, Reem , Maselli, Daniel B. , Abu Dayyeh, Barham K, Matar, Reem , Beran, Azizullah , Storm, Andrew C. , Dayyeh, Barham K. Abu

Mayo Clinic

Clinical and Translational Gastroenterology | September 21, 2020 | Volume: 11 | Issue: 9 | Pages: e00234

10.14309/ctg.0000000000000234 | PMID 33094961 Get It

INTRODUCTION: Endoscopic bariatric and metabolic therapies can potentially reproduce similar gastric and small intestinal anatomic and physiologic manipulations as Roux-en-Y gastric bypass. This proof of concept animal study was aimed to assess the feasibility, safety, efficacy, and impact on gastrointestinal physiology of combined intragastric balloons (IGB) and duodenal-jejunal bypass liner (DJBL) for the treatment of obesity. METHODS: Five Ossabaw pigs were fed a high-calorie diet to develop obesity and were randomly assigned to receive IGB or DJBL in sequence. The weight gain rate was calculated. Fasting and postprandial blood samples were drawn before any intervention (serving as the baseline group) and 1 month after second device insertion (serving as the combination group) to measure gut neurohormonal changes and metabolic parameters. RESULTS: Four pigs successfully received a sequential device insertion. One pig developed duodenal sleeve prolapse that was spontaneously resolved. One pig was early terminated because of developing a central line infection. The rate of weight gain in the combination group (0.63 ± 1.3 kg/wk) was significantly lower than the baseline group (1.96 ± 2.17 kg/wk) and numerically lower than after insertion of the IGB (1.00 ± 1.40 kg/wk) or the DJBL (0.75 ± 2.27 kg/wk) alone. A trend of higher postprandial glucagon-like peptide-1 was observed in the combination group compared with the baseline group. DISCUSSION: A combination of IGB and DJBL is feasible and well tolerated. A strategy of sequential use of these devices might offer a synergistic approach that can enhance weight loss and metabolic outcomes.